Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

234 results about "Thyreoidin" patented technology

Tricyclic-carbonyl-nitrogen heterocyclic derivatives and use thereof

The invention relates to PRMT5 inhibitors of formula (I), a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, a pharmaceutically acceptable salt of the atropisomer thereof, or a deuterated molecule thereof, and pharmaceutical compositions thereof, as well as the use thereof.
Owner:BEIJING DOUBLE-CRANE RUNCHUANG TECHNOLOGY CO LTD

Rnai reagent and composition for inhibiting expression of transthyretin (TTR), and use

PCT designated stage expiredWO2025098117A1Organic active ingredientsNervous disorderDiseaseSystemic amyloidosis
An RNAi agent and composition for inhibiting the expression of transthyretin (TTR), which can be used for treating and / or preventing ATTR-related diseases comprising ATTR-PN (transthyretin amyloidosis polyneuropathy), ATTR-CM (transthyretin amyloidosis cardiomyopathy), senile systemic amyloidosis diseases, and leptomeningeal / central nervous system amyloidosis diseases.
Owner:CHENGDU BRILLIANT PHARMA CO LTD

Thyromimetics for treatment of alopecia areata

Disclosed is a method for preventing, treating, or ameliorating alopecia areata, comprising administering a therapeutically effective amount of a thyromimetic compound or a pharmaceutically acceptable salt thereof to a subject in need thereof, wherein said thyromimetic compound is a compound of Formula I, wherein R1,R2,R3,R4,R5,R6,R7,R8,R9,G,T,and X are defined as herein.
Owner:ASCLETIS PHARMA (CHINA) CO LTD

Methods for treating or preventing thyroxine transporter mediated amyloidosis

Provided herein are anti-TTR antibody dosing regimens useful for the treatment of thyroxine transporter amyloid cardiomyopathy (ATTR-CM) in adult patients. In an embodiment, the patient is treated with an anti-TTR antibody comprising NI006 / ALXN2220.
Owner:NEURIMMUNE AG +1

Transthyretin immunoglobulin fusions

The present invention relates to transthyretin (TTR) fusions useful in the dimerization and tetramerization of antibodies and antibody fragments, such as Fabs. The TTR fusions proteins described herein are particularly useful in increasing antibody avidity and in enhancing antigen clustering. Methods for treating diseases using the fusion proteins of the present invention are described herein.
Owner:AMGEN INC

Stable levothyroxine compositions in aprotic polar solvents

The present invention concerns the use of aprotic polar solvents and an ionization stabilizing agent to prepare stable therapeutic formulations of levothyroxine by dissolving levothyroxine in an aprotic polar solvent system that can then be used to treat, prevent, and / or diagnose certain diseases and disorders in humans and veterinary animals by administration of the formulation thereto. In certain embodiments, the invention is directed to formulations comprising levothyroxine, and optionally one or more additional therapeutic agents, dissolved in an aprotic polar solvent system, such as a DMSO / water admixture comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent. The invention also provides methods of use of such formulations in treating, preventing, and / or diagnosing diseases and disorders, and methods of manufacturing such formulations.
Owner:XERIS PHARMACEUTICALS INC

Biomarker combination for early screening and diagnosis of transthyretin cardiac amyloidosis and application thereof

The invention provides application of a biomarker combination for early screening and diagnosis of transthyretin cardiac amyloidosis (ATTR-CA) high-risk groups in preparation of a product for early screening and diagnosis of the ATTR-CA high-risk groups. In general, one or more biomarkers, such as total prealbumin (total PA), transthyretin (TTR) tetramer, misfolded protein, protein misfolding rate, and soluble growth stimulus expression gene 2 protein (sST2). In ATTR-CA high-risk groups and non-high-risk groups, the biomarkers show significant difference, which prompts that the biomarkers are related to ATTR-CA. When a plurality of biomarkers are combined for use, the biomarkers have relatively high sensitivity and specificity in early screening and diagnosis of ATTR-CA high-risk groups, have relatively high diagnosis efficiency, and provide a new thought and strategy for early diagnosis and treatment of ATTR-CA.
Owner:SHANGHAI INST FOR BIOMEDICAL & PHARM TECH

Thyromimetics

Compounds are provided having the structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R1, R2, X1, X2, Y1, and Y2 are as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.
Owner:AUTOBAHN THERAPEUTICS INC

Sustained release injectable pharmaceutical formulation of levothyroxine and process for preparation thereof

A stable sustained release injectable formulation based on poly(D,L-lactide-co-glycolide) microparticles comprising levothyroxine is described. The formulation has a theoretical levothyroxine loading of at least 1.5% w / w. A process for preparing the microparticles is also described. The formulation may be used to control hypothyroidism in adults, congenital hypothyroidism in infants, and acquired hypothyroidism in children.
Owner:PHARMATHEN SA

Methods and compositions for treating transthyretin (TTR)- associated diseases

The invention relates to methods of treating subjects that would benefit from reduction in expression of transthyretin (TTR), such as subjects having a TTR-associated disease, disorder, or condition, e.g., transthyretin-mediated amyloidosis, or Stargardt disease, using double-stranded ribonucleic acid (dsRNA) compositions targeting the TTR gene. The invention also provides methods for preventing at least one symptom in a subject having a TTR-associated disease, disorder, or condition, e.g., transthyretin-mediated amyloidosis, or Stargardt disease.
Owner:ALNYLAM PHARMACEUTICALS INC

Methods of treating TTR amyloidosis using AG10

Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects.
Owner:EIDOS THERAPEUTICS INC

Novel monoclonal antibodies directed against l-thyroxine and diagnostic uses thereof

The present invention provides a novel monoclonal antibody specifically binding to L-Thyroxine (T4) and compositions and kits comprising such antibodies. Furthermore, provided are polynucleotides encoding such monoclonal antibodies, host cells expressing said antibodies, methods of producing such antibodies and diagnostic methods using such monoclonal antibodies. The monoclonal antibody of the invention comprises a heavy chain variable domain (VH) comprising V or A in position 33; Y in position 50; W in position 52; I in position 98, G, A or V in position 99; Y in position 100; and I in position 100b; and a light chain variable domain (VL) comprising amino acids H or Y in position 28; N or K in position 29; W in position 32; G or A in position 91; Y, W or F in position 92; S or T in position 93; Y or F in position 95b; N, S, T or Q in position 95c; and H in position 96, wherein the positions of the amino acids in the VH and the VL are indicated according to the Kabat numbering scheme, respectively.
Owner:ROCHE DIAGNOSTICS OPERATIONS INC

Multispecific thyroxine transporter immunoglobulin fusion

The present invention relates to multispecific thyroxine transporter (TTR) complexes useful as multispecific binding proteins. The multispecific TTR complexes described herein are particularly useful in binding to one, two or more epitopes that may be present on one or more proteins. Methods of treating diseases using the TTR complexes of the invention are described herein.
Owner:AMGEN INC

Pharmaceutical composition containing thyroxine receptor stimulant and folic acid substances

The invention provides a pharmaceutical composition. The pharmaceutical composition is composed of a thyroxine receptor beta agonist, folic acid substances and pharmaceutically acceptable auxiliary materials. The invention also relates to application of the composition in preparation of drugs for treating chronic fatty liver diseases. The pharmaceutical composition has the advantages that the pharmaceutical composition can be used for treating the fatty liver accompanied by hypothyroidism, and adverse reactions generated by independently taking a thyroid receptor beta agonist can be reduced.
Owner:SHENZHEN AUSA PHARM CO LTD +1

New co-drug, co-administration and sequential administration of selective ttr ligands that eliminate mechanism-based ocular adverse reactions in the treatment of macular degeneration and ttr amyloidosis with c20-d3-retinol

PendingCN122341593ARetinoidRetinaldehyde
Based on co-drugs representing two different chemical entities and the co- and sequential administration of the two chemical entities, novel therapies for macular degeneration and TTR amyloidosis are provided. The first component (“selective TTR ligand”) is a chemical entity that binds to TTR in the RBP4 (retinol-binding protein 4)-TTR (transthyretin) complex, which participates in the delivery of retinol to the retina. This component reduces retinol transport from circulation to the retina and provides stabilization of the TTR tetramer. The second component (“C20-D3-visual chromophore-generating compound”) is a C20-D3 modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore, which is presented in the retina as C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at C20 reduces the formation of lipofuscin biretinol, but other functions (such as providing a precursor for the synthesis of the visual chromophore 11-cis-retinaldehyde in vivo) are not reduced.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1

Thyroid hormone receptor beta agonist compounds

ActiveCN112805005BOrganic active ingredientsOrganic chemistryThyroid hormone receptor betaAgonist
Provided herein are compounds, preferably thyroid hormone receptor beta, THRbeta, agonist compounds, compositions thereof, and methods of making the same, and methods of agonizing THRbeta, and methods for treating conditions mediated by THRbeta.
Owner:TERNS INC

Transthyretin antibodies and uses thereof

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human transthyretin (TTR). The anti-TTR antibodies or antigen-binding fragments thereof are useful, for example, in detecting TTR and in treating TTR amyloidosis in a subject.
Owner:MOR RES APPL LTD

Desloratadine solid preparation

To provide a desloratadine solid preparation that suppresses the time-dependent increase in analogs and exhibits superior stability.SOLUTION: The present invention provides a desloratadine solid preparation containing desloratadine and arginine, thereby suppressing the time-dependent increase in analogs, particularly N-formyl desloratadine. The solid preparation is preferably an orally disintegrating tablet.SELECTED DRAWING: None
Owner:TAKATA SEIYAKU

Thiroxine beta receptor selective agonist compounds, pharmaceutical compositions and uses thereof

The present invention relates to thyroxine beta receptor selective agonist compounds, pharmaceutical compositions and uses thereof. Specifically, the invention relates to a compound as shown in a formula (I). The compound provided by the invention has excellent drug effect and / or specificity, and can be used for treating metabolism-related diseases.
Owner:SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES +1

Sirna therapy for transthyretin (TTR) related ocular amyloidosis

The invention relates to a method of treating ocular amyloidosis by reducing TTR expression in a subject by administering a double-stranded ribonucleic acid (dsRNA) that targets a TTR gene to the retinal pigment epithelium of the subject.
Owner:ALNYLAM PHARMACEUTICALS INC +1

Novel co-drug, co-administration, and sequential administration of bispecific RBP4 / TTR ligand and c20-d3-retinol for elimination of mechanism-based ocular adverse effects in treating macular degeneration and TTR amyloidosis

PCT designated stage expiredWO2024263782A2Group 4/14 element organic compoundsSenses disorderRetinoidRetinaldehyde
New therapies for macular degeneration and TTR amyloidosis are provided based on a co-drug that represents a conjugate of two distinct chemical entities as well as co- administration and sequential administration of the two chemical entities. The first component ("bispecific RBP4 / TTR ligand") is a chemical entity that engages TTR ( transthyretin) and RBP4 ( retinol binding protein 4 ) of the RBP4 -TTR complex, which is involved in delivery of retinol to the retina. This component reduces traffic of retinol from circulation to the retina and provides stabilization of TTR tetramers. The second component ("C20-D3-visual-chromophore-producing compound" ) is a C20 -D3 -modified retinoid or carotenoid that upon metabolism in a mammal can eventually produce a C20-D3 visual chromophore that represents C20 -D3- 9-cis-retinaldehyde or C20-D3-11-cis-retinaldehyde in the retina. Deuteration at the C20 position reduces the formation of lipofuscin bisretinoid while other functions ( such as providing a precursor for in vivo synthesis of the visual chromophore, 11-cis-retinaldehyde ) are not reduced.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1

Human umbilical cord composition for treating Petroleum disease

A treated human umbilical cord composition for use in the treatment of Perony's disease by in vivo injection in a subject in need thereof using an effective amount of the composition. The composition comprises a water-based human umbilical cord filtrate, wherein endogenous hyaluronic acid (HA) and / or hyaluronic acid, fibronectin, insulin growth factor binding protein-1 (IGFBP-1), sulfated glycosaminoglycan (sGAG), exosomes, interleukin-1 receptor antagonist (IL-1ra), hepatocyte growth factor (HGF), transthyretin, metalloproteinase tissue inhibitor 1 (TIMP-1), and / or a pharmaceutically acceptable salt thereof in an amount effective to reduce the size of Pteroid disease plaques. The present invention relates to an aggregation glycan, or a combination thereof.
Owner:BIOSTEM TECHNOLOGIES INC

Modified-release tolcapone formulation

A modified-release tablet dosage form containing tolcapone is disclosed. The tablet dosage form provides a pulsatile, pH-dependent release profile of tolcapone to both the gastric cavity and the small intestine. Methods for treating or preventing a disease selected from transthyretin amyloidosis (ATTR), Parkinson's disease, and obsessive-compulsive disorder using the dosage form are provided.
Owner:CORINO THERAPEUTICS INC

Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition

The invention relates to a conjugate for transferring an effector molecule from outside a cell into said cell, the conjugate comprising at least one effector molecule to be transferred into the cell, at least one saponin of the mono-desmosidic triterpene glycoside type or the bi-desmosidic triterpene glycoside type, and at least one single-domain antibody (sdAb), covalently bound to each other, wherein the sdAb is capable of binding to a cell-surface molecule of said cell. The invention also relates to a pharmaceutical composition comprising the conjugate of the invention. Furthermore, the invention relates to a pharmaceutical composition of the invention, for use as a medicament. In addition, the invention relates to a pharmaceutical composition of the invention, for use in the treatment or the prophylaxis of any one or more of: a cancer, an auto-immune disease such as rheumatoid arthritis, an enzyme deficiency, a disease related to an enzyme deficiency, a gene defect, a disease relating to a gene defect, an infection such as a viral infection, hypercholesterolemia, primary hyperoxaluria, haemophilia A, haemophilia B, alpha-1 antitrypsin related liver disease, acute hepatic porphyria, an amyloidosis and transthyretin-mediated amyloidosis. The invention also relates to an in vitro or ex vivo method for transferring the conjugate from outside a cell to inside said cell or for transferring the effector molecule comprised by the conjugate of the invention from outside a cell to inside said cell, preferably to the cytosol of said cell.
Owner:SAPREME TECH BV

A method for constructing an osteoarthritis cartilage organoid and application thereof

The application discloses a construction method and application of an osteoarthritis cartilage organoid, and the method comprises the following steps: 1) mesenchymal stem cells are inoculated on a round bottom culture plate by a Micromass method, and are cultured in a chondrogenic induction culture medium containing dexamethasone, ascorbic acid and TGF-beta 3 for 10-18 days to form a transparent cartilage organoid; and 2) the transparent cartilage organoid is placed in an osteoarthritis induction culture medium containing dexamethasone, L-thyroxine, inflammatory factors (IL-1beta, IL-6 and TNF-alpha) and beta-glycerophosphate sodium for continuous culture for 5-10 days to obtain an osteoarthritis cartilage organoid; the model simultaneously presents multi-dimensional pathological characteristics such as matrix degeneration, hypertrophy, inflammation activation and vascularization trend, and can be used for osteoarthritis pathogenesis research, drug screening and cell treatment effect evaluation; the construction method is controllable and has good repeatability, and provides a reliable three-dimensional in-vitro model for osteoarthritis research.
Owner:PEOPLES HOSPITAL PEKING UNIV

Online separation and valuing method for free thyroxine in serum

ActiveCN119985825AComponent separationSolid phase extractionFree thyroid hormone
The invention discloses an on-line separation and valuing method for free thyroxine in serum. The method comprises the following steps: (1) setting a two-dimensional liquid chromatogram; (2) on-line separation and removal of macromolecular interferents in the serum; (3) retaining free thyroid hormone; (4) on-line separation of free thyroid hormone; (5) on-line valuing by isotope dilution mass spectrometry; and (6) cleaning the two-dimensional liquid chromatography system. The method provided by the invention realizes on-line separation of free thyroid hormone in serum and absolute constant value. A first-dimensional chromatographic mobile phase is a mild ammonium salt buffer solution and does not contain an organic solvent, so that thyroid hormones combined with protein in serum can be kept in a combined state, and a target object entering mass spectrometry is free thyroid hormones; and the valuing result can be traced to the international unit system through the national certified standard substance. Compared with traditional serum off-line treatment modes such as solid-phase extraction and equilibrium dialysis, the method has the characteristics of high efficiency, reliability and easiness in operation.
Owner:NATIONAL INSTITUTE OF METROLOGY CHINA

Anti-thyroid hormone (T4) recombinant antibody or antigen-binding fragment

The present invention relates to the field of antibodies, antigen-binding fragments and immunodiagnosis. Specifically, the present invention relates to recombinant antibodies or antigen-binding fragments for binding thyroid hormone T4 (thyroxine) and halogenated bisphenol A. Furthermore, the present invention relates to isolated nucleic acid molecules comprising nucleotide sequences encoding the recombinant antibodies or antigen-binding fragments of the present invention, as well as expression vectors and host cells comprising the nucleic acid molecules of the present invention. In addition, the present invention relates to methods for producing recombinant antibodies or antigen-binding fragments for binding T4 thyroid hormone and halogenated bisphenol A, test kits and immunoassays comprising the recombinant antibodies or antigen-binding fragments of the present invention, and methods for determining the levels of T4 thyroid hormone and / or halogenated bisphenol A in a sample of a subject. Furthermore, the present invention relates to methods for processing samples, such as immunoaffinity-based sample preparation methods for enriching halogenated bisphenol A from a sample.
Owner:TEKNOLOGIAN TUTKIMUSKESKUS VTT OY +1

Compositions and methods for treating pulmonary edema or lung inflammation

A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.
Owner:REGENTS OF THE UNIVERSITY OF MINNESOTA

Transthyretin biomarkers for detecting and monitoring cancers

PCT designated stageWO2026113519A1Material analysisBiologic markerBlood plasma
Disclosed is a method for diagnosing a cancer health state, or a change in cancer health state in a patient, or for diagnosing a risk of the change or presence of a cancer in a patient, comprising determining, in a plasma sample from said patient, one or more biomarker values that correspond to transthyretin-containing complex structures, and assigning the patient as having or not having cancer, or having or not having a change in cancer health state, or having or not having a risk of cancer based on said biomarker values, wherein said cancer is preferably lung cancer (LC).
Owner:SUN JET BIOTECH INC